Table 4.
Clinicopathological features of the patients carrying both EGFR exon 19 E746_A750 deletions and exon 21 L858R mutation (n=4)
| Clinicopathological parameters | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Age (year) | 59 | 72 | 45 | 63 |
| Sex | Male | Female | Female | Female |
| Smoking | Former smoker | Never smoker | Never smoker | Never smoker |
| TNM stage | IIIb | IV | IV | IV |
| IHC markers | ||||
| CK-7 | + | + | + | + |
| TTF-1 | + | + | + | + |
| Napsin-A | + | + | + | + |
| ALK | − | − | − | − |
| Ki67 index (%) | 10 | 20 | 5 | 15 |
| E746_A750del score | 2+ | 2+ | 3+ | 3+ |
| L858R mutation score | 2+ | 2+ | 3+ | 2+ |
| Growth pattern | Acinar | Acinar | Lepidic | Papillary |
| PFS (months) | 12.5 | 13 | 15 | 14.5 |
Abbreviations: EGFR, epidermal growth factor receptor; TNM, tumor-node-metastasis; CK-7, cytokeratin-7; TTF-1, thyroid transcription factor-1; IHC, immunohistochemistry; PFS, progression-free survival; ALK, anaplastic lymphoma kinase.